Non-Invasive Technology Evaluated to Treat Cardiac Chest Pain

May 19, 2010 By Jackie Carr
UC San Diego Medical Center is evaluating non-invasive shock wave technology for the treatment of angina.

(PhysOrg.com) -- UC San Diego Health System is enrolling a small group of patients in a two-year study to examine the safety of a non-invasive cardiac shock wave procedure for patients with chest pain caused by insufficient blood flow to the heart.

Angina pectoris is a debilitating form of pain that affects more than ten million people in the U.S., according to the American Heart Association. Traditional angina treatments include drug therapy, angioplasty and graft surgery. Despite these therapies, many patients continue to experience the squeezing pain or pressure of continual angina pectoris.

Cardiac shock wave technology sends low-intensity energy to specific areas of the heart to stimulate the growth of new blood vessels and relieve pain. It uses technology similar to, but of lower strength than Extracorporeal Shock Wave Lithotripsy (ESWL) that is used in the treatment of kidney stones.

“These acoustic are not dissolving plaque in the same way that lithotripsy breaks up a stone,” said Anthony DeMaria, MD, cardiologist and principal investigator of the clinical trial at UC San Diego Medical Center. “Instead, these waves energize the heart tissue to release substances which, in turn, stimulate the formation of new blood vessels in the heart.”

The shock wave schedule consists of three 20-minute sessions per week over nine weeks. Patients who participate in this study will be evaluated at two and four-month intervals after the last treatment. Evaluations include a physical exam, treadmill tests, blood work, a drug induced stress/rest test, and a discussion of any adverse events or complications.

“This potential therapeutic approach is an alternative for patients who continue to have from angina, even though they take medicine, and are not candidates for a stent or bypass operation,” said DeMaria, associate dean for Outreach and Development for Health Sciences at UC San Diego and editor-in-chief of the Journal of the American College of Cardiology.

A maximum of 15 U.S. patients will be evaluated in this multicenter Phase I trial sponsored by Medispec Ltd., to assess the safety of Cardiospec™ Extracorporeal Shockwave Myocardial Revascularization (ESMR).

Explore further: 3-D printing offers innovative method to deliver medication

add to favorites email to friend print save as pdf

Related Stories

Your own stem cells can treat heart disease

Nov 17, 2009

The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ...

Squeezing 'pants' good fit for some heart patients

Feb 04, 2010

(PhysOrg.com) -- Squeezing into a tight pair of pants can be a painful experience, but a new type of "pants" recommended for certain heart patients actually squeezes back and provides pain relief.

Recommended for you

Owls and lizards lend their ears for human hearing research

11 hours ago

Lizards and owls are some of the animal species that can help us to better understand hearing loss in humans, according to new research out of York University's Department of Physics & Astronomy in the Faculty of Science.

Team finds key to tuberculosis resistance

16 hours ago

The cascade of events leading to bacterial infection and the immune response is mostly understood. However, the molecular mechanisms underlying the immune response to the bacteria that causes tuberculosis ...

Mutation may cause early loss of sperm supply

17 hours ago

Brown University biologists have determined how the loss of a gene in male mice results in the premature exhaustion of their fertility. Their fundamental new insights into the complex process of sperm generation ...

No more bleeding for 'iron overload' patients?

19 hours ago

Hemochromatosis (HH) is the most common genetic disorder in the western world, and yet is barely known. Only in the US 1 in 9 people carry the mutation (although not necessarily the disease).

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.